STOCK TITAN

Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Viridian Therapeutics (NASDAQ: VRDN) announced a webcast and conference call on March 8, 2023, at 8:00 a.m. ET to discuss its Q4 and full-year 2022 financial results. The session can be accessed via the company’s website under the ‘Events and Presentations’ section. Viridian focuses on developing best-in-class medicines for serious and rare diseases, with ongoing clinical trials for its lead candidate, VRDN-001, targeting thyroid eye disease (TED). The company is conducting a global Phase 3 trial named ‘THRIVE’ and a Phase 2 trial, broadening its pipeline with additional candidates aimed at improving treatment delivery for TED patients.

Positive
  • Initiation of Phase 3 'THRIVE' trial for VRDN-001 in TED patients.
  • Multiple ongoing clinical trials enhance the pipeline visibility.
  • Focus on developing differentiated therapies for rare diseases.
Negative
  • None.

WALTHAM, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, March 8, 2023 at 8:00 a.m. ET to discuss its fourth quarter and full year 2022 financial results.

The webcast can be accessed under “Events and Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com. To participate in the conference call, please dial 1-877-407-0789 (domestic) or 1-201-689-8562 (international) and reference code 13736278. A replay of the webcast will be available following the completion of the event.

About Viridian Therapeutics

Viridian Therapeutics is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and engineering enables it to develop differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company recently initiated its first global Phase 3 trial called ‘THRIVE’ to evaluate the safety and efficacy of VRDN-001 in patients with active TED. Viridian is also evaluating VRDN-001 in a Phase 2 proof-of-concept trial in patients with chronic TED. In addition to its intravenously administered VRDN-001 program, the Company is advancing two candidates for its subcutaneous strategy with the goal of providing a more conveniently administered therapy to patients with TED. Viridian is developing multiple preclinical assets in autoimmune and rare diseases.

Viridian is based in Waltham, Massachusetts. For more information, please visit https://www.viridiantherapeutics.com. Follow Viridian on LinkedIn.

Contacts

Source: Viridian Therapeutics, Inc.

Investors:
Todd James, 617-272-4691
Senior Vice President, Corporate Affairs and Investor Relations
IR@viridiantherapeutics.com

Louisa Stone, 617-272-4604
Manager, Investor Relations
IR@viridiantherapeutics.com

Media:
Matt Fearer, 617-272-4605
Vice President, Corporate Communications
Media@viridiantherapeutics.com  


FAQ

What is the date of Viridian Therapeutics' upcoming financial results call?

Viridian Therapeutics will host its financial results call on March 8, 2023.

What is the key focus of Viridian Therapeutics?

Viridian Therapeutics focuses on developing potential best-in-class medicines for serious and rare diseases.

What clinical trials is Viridian currently conducting?

Viridian is conducting a global Phase 3 trial for VRDN-001 in thyroid eye disease and a Phase 2 proof-of-concept trial for chronic TED.

How can I access the Viridian Therapeutics financial results call?

The financial results call can be accessed via the Investors section of the Viridian Therapeutics website.

Viridian Therapeutics, Inc.

NASDAQ:VRDN

VRDN Rankings

VRDN Latest News

VRDN Stock Data

1.59B
76.37M
0.01%
112%
13.12%
Biotechnology
Services-medical Laboratories
Link
United States of America
WALTHAM